RUBY — Rubius Therapeutics, Inc USA

HealthcareBiotechnology

[[ lastPrice | number : 2]]
[[ refundPrice | number : 2]]
[[ refundPriceP | number : 2]]%
[[ lastDate * 1000 | date:'MMM d, y @h:mm a' ]]
Currency in USD
Key statistics
Basic
Not enough data for Risks (Volatility).
Not enough data for Beta calculations.
Market capital
$680M
Employees
206
Money
Not enough data for Earnings per share statistics.
Not enough data for Book Value calculations.
Wall Street price
$24.00
PE Ratio
Dividends
Volume & Social
Short Ratio
27.09%
Daily Volume
276,100
Volume
Average
Social Rate
Untracked
Social Volume
Untracked
 
Latest RUBY news
[[ item.source ]] - [[ item.pubDate | date:'MMM d, y @ h:mma' ]]
[[ item.description ]]
Invest ideas
2 ideas for buy
181.03%
Wall Street Higher
Fundamental signal
The price is expected to raise
0.83x
PB Ratio lower than sector
Fundamental signal
Price-to-Book lower than sector.
5 ideas for sell
-$1.7
Earnings are negative
Fundamental signal
Earnings per share are negative
0.83x
PB Ratio higher than industry
Fundamental signal
Price-to-Book Ratio is higher than industry.
679.25%
Short Ratio higher than industry
Fundamental signal
Short Interest Ratio is higher than industry.
717.24%
Short Ratio higher than sector
Fundamental signal
Short Interest Ratio is higher than sector.
-39.44%
Below SMA 200
Technical signal
The price is below SMA for 200 days period
Invest Ideas — the best way to get insights based on both fundamental and technical data. We analyze company's performance across sector and industry and generate investing ideas for you.
Want to track signal changes?
It's easy to monitor changes in signal with our watchlist. Just add the stock to your watchlist and get daily, weekly and monthly signal changes for the asset.
Similar and Opposite stocks
Most and less correlated stocks. All correllations are calculated for 1 year period. Learn more about correlations.
Similar (most correlated) stocks
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Correlation
100.00%
UB Rating
Opposite (less correlated) stocks
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Correlation
−100.00%
UB Rating
Income Statement
All numbers in thousands [[fin.date | strtotimestamp | date: 'MMM d, yyyy']]
Revenue
Total Revenue [[fin.totalRevenue / 1000 | number : 0]]
Cost of Revenue [[fin.costOfRevenue / 1000 | number : 0]]
Gross Profit [[fin.grossProfit / 1000 | number : 0]]
Operating Expenses
Research Development [[fin.researchDevelopment / 1000 | number : 0]]
Selling General and Administrative [[fin.sellingGeneralAdministrative / 1000 | number : 0]]
Non Recurring [[fin.nonRecurring / 1000 | number : 0]]
Others [[fin.otherOperatingExpenses / 1000 | number : 0]]
Total Operating Expenses [[fin.totalOperatingExpenses / 1000 | number : 0]]
Operating Income or Loss [[fin.operatingIncome / 1000 | number : 0]]
Income from Continuing Operations
Total Other Income/Expenses Net [[fin.totalOtherIncomeExpenseNet / 1000 | number : 0]]
Earnings Before Interest and Taxes [[fin.ebit / 1000 | number : 0]]
Interest Expense [[fin.interestExpense / 1000 | number : 0]]
Income Before Tax [[fin.incomeBeforeTax / 1000 | number : 0]]
Income Tax Expense [[fin.incomeTaxExpense / 1000 | number : 0]]
Minority Interest [[fin.minorityInterest / 1000 | number : 0]]
Net Income From Continuing Ops [[fin.netIncomeFromContinuingOps / 1000 | number : 0]]
Non-recurring Events
Discontinued Operations [[fin.discontinuedOperations / 1000 | number : 0]]
Extraordinary Items [[fin.extraordinaryItems / 1000 | number : 0]]
Effect Of Accounting Changes [[fin.effectOfAccountingCharges / 1000 | number : 0]]
Other Items [[fin.otherItems / 1000 | number : 0]]
Net Income
Net Income [[fin.netIncome / 1000 | number : 0]]
Net Income Applicable To Common Shares [[fin.netIncomeApplicableToCommonShares / 1000 | number : 0]]
Balance Sheet
All numbers in thousands [[fin.date | strtotimestamp | date: 'MMM d, yyyy']]
Current Assets  
Cash And Cash Equivalents [[fin.cash / 1000 | number : 0]]
Short Term Investments [[fin.shortTermInvestments / 1000 | number : 0]]
Net Receivables [[fin.netReceivables/ 1000 | number : 0]]
Inventory [[fin.inventory/ 1000 | number : 0]]
Other Current Assets [[fin.otherCurrentAssets/ 1000 | number : 0]]
Total Current Assets [[fin.totalCurrentAssets / 1000 | number : 0]]
Long Term Investments [[fin.longTermInvestments / 1000 | number : 0]]
Property Plant and Equipment [[fin.propertyPlantEquipment / 1000 | number : 0]]
Goodwill [[fin.goodWill / 1000 | number : 0]]
Intangible Assets [[fin.intangibleAssets / 1000 | number : 0]]
Other Assets [[fin.otherAssets / 1000 | number : 0]]
Total Assets [[fin.totalAssets / 1000 | number : 0]]
Current Liabilities
Accounts Payable [[fin.accountsPayable / 1000 | number : 0]]
Short/Current Long Term Debt [[fin.shortLongTermDebt / 1000 | number : 0]]
Other Current Liabilities [[fin.otherCurrentLiab / 1000 | number : 0]]
Total Current Liabilities [[fin.totalCurrentLiabilities / 1000 | number : 0]]
Long Term Debt [[fin.longTermDebt / 1000 | number : 0]]
Other Liabilities [[fin.otherLiab / 1000 | number : 0]]
Deferred Long Term Liability Charges [[fin.deferredLongTermLiab / 1000 | number : 0]]
Total Liabilities [[fin.totalLiab / 1000 | number : 0]]
Stockholders' Equity
Common Stock [[fin.commonStock / 1000 | number : 0]]
Retained Earnings [[fin.retainedEarnings / 1000 | number : 0]]
Other Stockholder Equity [[fin.otherStockholderEquity / 1000 | number : 0]]
Total Stockholder Equity [[fin.totalStockholderEquity / 1000 | number : 0]]
Net Tangible Assets [[fin.netTangibleAssets / 1000 | number : 0]]
Cash Flow Statement
All numbers in thousands [[fin.date | strtotimestamp | date: 'MMM d, yyyy']]
Net Income [[fin.netIncome/ 1000 | number : 0]]
Operating Activities, Cash Flows Provided By or Used In
Depreciation [[fin.depreciation / 1000 | number : 0]]
Adjustments To Net Income [[fin.changeToNetincome / 1000 | number : 0]]
Changes In Accounts Receivables [[fin.changeToAccountReceivables / 1000 | number : 0]]
Changes In Liabilities [[fin.changeToLiabilities / 1000 | number : 0]]
Changes In Inventories [[fin.changeToInventory / 1000 | number : 0]]
Changes In Other Operating Activities [[fin.changeToOperatingActivities / 1000 | number : 0]]
Total Cash Flow From Operating Activities [[fin.totalCashFromOperatingActivities / 1000 | number : 0]]
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures [[fin.capitalExpenditures / 1000 | number : 0]]
Investments [[fin.investments / 1000 | number : 0]]
Other Cash flows from Investing Activities [[fin.otherCashflowsFromInvestingActivities / 1000 | number : 0]]
Total Cash Flows From Investing Activities [[fin.totalCashflowsFromInvestingActivities / 1000 | number : 0]]
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid [[fin.dividendsPaid / 1000 | number : 0]]
Sale Purchase of Stock [[fin.salePurchaseOfStock / 1000 | number : 0]]
Net Borrowings [[fin.netBorrowings / 1000 | number : 0]]
Other Cash Flows from Financing Activities [[fin.otherCashflowsFromFinancingActivities / 1000 | number : 0]]
Total Cash Flows From Financing Activities [[fin.totalCashFromFinancingActivities / 1000 | number : 0]]
Change In Cash and Cash Equivalents [[fin.changeInCash / 1000 | number : 0]]
 

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 206
Avg
-0.57 -2.02 -1.58
High
-0.45 -1.75 -0.93
Low
-0.68 -2.23 -2.20
Avg
0 0 0
High
0 0 0
Low
0 0 0
  [[fin.date | strtotimestamp | date: 'MMM d,yyyy']]
Earnings History
Earnings Actual [[fin.epsActual | number : 2]]
Earnings Estimate [[fin.epsEstimate | number : 2]]
Difference [[fin.epsDifference | number : 2]]
Surprise [[fin.surprisePercent | number : 1]]%
  Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']])
Earnings Estimate
Number of Analysts [[financials['etrend']['0q'].earningsEstimateNumberOfAnalysts | number : 0]] [[financials['etrend']['+1q'].earningsEstimateNumberOfAnalysts | number : 0]] [[financials['etrend']['0y'].earningsEstimateNumberOfAnalysts | number : 0]] [[financials['etrend']['+1y'].earningsEstimateNumberOfAnalysts | number : 0]]
Estimate Average [[financials['etrend']['0q'].earningsEstimateAvg | number : 2]] [[financials['etrend']['+1q'].earningsEstimateAvg | number : 2]] [[financials['etrend']['0y'].earningsEstimateAvg | number : 2]] [[financials['etrend']['+1y'].earningsEstimateAvg | number : 2]]
Estimate High [[financials['etrend']['0q'].earningsEstimateHigh | number : 2]] [[financials['etrend']['+1q'].earningsEstimateHigh | number : 2]] [[financials['etrend']['0y'].earningsEstimateHigh | number : 2]] [[financials['etrend']['+1y'].earningsEstimateHigh | number : 2]]
Estimate Low [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] [[financials['etrend']['0q'].earningsEstimateLow | number : 2]] [[financials['etrend']['0y'].earningsEstimateLow | number : 2]] [[financials['etrend']['+1y'].earningsEstimateLow | number : 2]]
Estimate Growth [[financials['etrend']['0q'].earningsEstimateGrowth | number : 2]] [[financials['etrend']['+1q'].earningsEstimateGrowth | number : 2]] [[financials['etrend']['0y'].earningsEstimateGrowth | number : 2]] [[financials['etrend']['+1y'].earningsEstimateGrowth | number : 2]]
Year Ago EPS [[financials['etrend']['0q'].earningsEstimateYearAgoEps | number : 2]] [[financials['etrend']['+1q'].earningsEstimateYearAgoEps | number : 2]] [[financials['etrend']['0y'].earningsEstimateYearAgoEps | number : 2]] [[financials['etrend']['+1y'].earningsEstimateYearAgoEps | number : 2]]
All numbers in thousands (except analysts) Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']])
Revenue Estimate
Number of Analysts [[financials['etrend']['0q'].revenueEstimateNumberOfAnalysts | number : 0]] [[financials['etrend']['+1q'].revenueEstimateNumberOfAnalysts | number : 0]] [[financials['etrend']['0y'].revenueEstimateNumberOfAnalysts | number : 0]] [[financials['etrend']['+1y'].revenueEstimateNumberOfAnalysts | number : 0]]
Estimate Average [[financials['etrend']['0q'].revenueEstimateAvg / 1000 | number : 0]] [[financials['etrend']['+1q'].revenueEstimateAvg / 1000 | number : 0]] [[financials['etrend']['0y'].revenueEstimateAvg / 1000 | number : 0]] [[financials['etrend']['+1y'].revenueEstimateAvg / 1000 | number : 0]]
Estimate High [[financials['etrend']['0q'].revenueEstimateHigh / 1000 | number : 0]] [[financials['etrend']['+1q'].revenueEstimateHigh / 1000 | number : 0]] [[financials['etrend']['0y'].revenueEstimateHigh / 1000 | number : 0]] [[financials['etrend']['+1y'].revenueEstimateHigh / 1000 | number : 0]]
Estimate Low [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] [[financials['etrend']['0q'].revenueEstimateLow / 1000 | number : 0]] [[financials['etrend']['0y'].revenueEstimateLow / 1000 | number : 0]] [[financials['etrend']['+1y'].revenueEstimateLow / 1000 | number : 0]]
Estimate Growth [[financials['etrend']['0q'].revenueEstimateGrowth * 100 | number : 2]]% [[financials['etrend']['+1q'].revenueEstimateGrowth * 100 | number : 2]]% [[financials['etrend']['0y'].revenueEstimateGrowth * 100 | number : 2]]% [[financials['etrend']['+1y'].revenueEstimateGrowth * 100| number : 2]]%
Year Ago EPS [[financials['etrend']['0q'].revenueEstimateYearAgoEps | number : 0]] [[financials['etrend']['+1q'].revenueEstimateYearAgoEps | number : 0]] [[financials['etrend']['0y'].revenueEstimateYearAgoEps | number : 0]] [[financials['etrend']['+1y'].revenueEstimateYearAgoEps | number : 0]]
Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']])
EPS Trend
Current Estimate [[financials['etrend']['0q'].epsTrendCurrent | number : 2]] [[financials['etrend']['+1q'].epsTrendCurrent | number : 2]] [[financials['etrend']['0y'].epsTrendCurrent | number : 2]] [[financials['etrend']['+1y'].epsTrendCurrent | number : 2]]
7 Days Ago [[financials['etrend']['0q'].epsTrend7daysAgo | number : 2]] [[financials['etrend']['+1q'].epsTrend7daysAgo | number : 2]] [[financials['etrend']['0y'].epsTrend7daysAgo| number : 2]] [[financials['etrend']['+1y'].epsTrend7daysAgo | number : 2]]
30 Days Ago [[financials['etrend']['0q'].epsTrend30daysAgo | number : 2]] [[financials['etrend']['+1q'].epsTrend30daysAgo | number : 2]] [[financials['etrend']['0y'].epsTrend30daysAgo | number : 2]] [[financials['etrend']['+1y'].epsTrend30daysAgo | number : 2]]
60 Days Ago [[financials['etrend']['0q'].epsTrend60daysAgo | number : 2]] [[financials['etrend']['+1q'].epsTrend60daysAgo | number : 2]] [[financials['etrend']['0y'].epsTrend60daysAgo | number : 2]] [[financials['etrend']['+1y'].epsTrend60daysAgo | number : 2]]
90 Days Ago [[financials['etrend']['0q'].epsTrend90daysAgo | number : 2]] [[financials['etrend']['+1q'].epsTrend90daysAgo | number : 2]] [[financials['etrend']['0y'].epsTrend90daysAgo | number : 2]] [[financials['etrend']['+1y'].epsTrend90daysAgo | number : 2]]
Cur Qtr ([[financials['etrend']['0q'].date | strtotimestamp | date: 'MMM yyyy']]) Next Qtr ([[financials['etrend']['+1q'].date | strtotimestamp | date: 'MMM yyyy']]) Cur Year ([[financials['etrend']['0y'].date | strtotimestamp | date: 'MMM yyyy']]) Next Year ([[financials['etrend']['+1y'].date | strtotimestamp | date: 'MMM yyyy']])
EPS Revisions
Up Last 7 Days [[financials['etrend']['0q'].epsRevisionsUpLast7days | number : 0]] [[financials['etrend']['+1q'].epsRevisionsUpLast7days | number : 0]] [[financials['etrend']['0y'].epsRevisionsUpLast7days | number : 0]] [[financials['etrend']['+1y'].epsRevisionsUpLast7days | number : 0]]
Up Last 30 Days [[financials['etrend']['0q'].epsRevisionsUpLast30days | number : 0]] [[financials['etrend']['+1q'].epsRevisionsUpLast30days | number : 0]] [[financials['etrend']['0y'].epsRevisionsUpLast30days| number : 0]] [[financials['etrend']['+1y'].epsRevisionsUpLast30days | number : 0]]
Down Last 30 Days [[financials['etrend']['0q'].epsRevisionsDownLast30days | number : 0]] [[financials['etrend']['+1q'].epsRevisionsDownLast30days | number : 0]] [[financials['etrend']['0y'].epsRevisionsDownLast30days | number : 0]] [[financials['etrend']['+1y'].epsRevisionsDownLast30days | number : 0]]
Down Last 90 Days [[financials['etrend']['0q'].epsRevisionsDownLast90days | number : 0]] [[financials['etrend']['+1q'].epsRevisionsDownLast90days | number : 0]] [[financials['etrend']['0y'].epsRevisionsDownLast90days | number : 0]] [[financials['etrend']['+1y'].epsRevisionsDownLast90days | number : 0]]
 
Date Open High Low Close Volume
[[data.Date]] [[data.Open | number : 2]] [[data.High | number : 2]] [[data.Low | number : 2]] [[data.Close | number : 2]] [[data.Volume | number : 0]]